What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France

OBJECTIVES: New diagnostic criteria for Alzheimer’s disease (AD) include cerebrospinal fluid (CSF) biomarkers that allow diagnosis at the stage of mild cognitive impairment (MCI). However, the impact of CSF biomarkers in MCI populations in clinical practice has been poorly evaluated. The objective o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cognat, Emmanuel, Mouton Liger, François, Troussière, Anne-Cécile, Wallon, David, Dumurgier, Julien, Magnin, Eloi, Duron, Emmanuelle, Gabelle, Audrey, Croisile, Bernard, de la Sayette, Vincent, Jager, Alain, Blanc, Frederic, Bouaziz-Amar, Elodie, Miguet-Alfonsi, Carole, Quillard, Muriel, Schraen, Susanna, Philippi, Nathalie, Beaufils, Emilie, Pasquier, Florence, Hannequin, Didier, Robert, Philippe, Hugon, Jacques, Paquet, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549619/
https://www.ncbi.nlm.nih.gov/pubmed/31152032
http://dx.doi.org/10.1136/bmjopen-2018-026380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549619/
https://www.ncbi.nlm.nih.gov/pubmed/31152032
http://dx.doi.org/10.1136/bmjopen-2018-026380

Ejemplares similares